Local News

• Pfizer withdraws application to switch Viagra to non-prescription status in Europe  Pfizer announced that it has withdrawn its application to switch the legal status of the 50 mg tablet strength of Viagra from 'prescription only' to 'non-prescription' in the European Union (EU).
  Pfizer Inc. November 20, 2008  
• AstraZeneca granted temporary restraining order in PULMICORT RESPULES patent litigation  On 19 November 2008, AstraZeneca was granted a Temporary Restraining Order (TRO) by the United States District Court for the District of New Jersey, halting sales of Teva's budesonide inhalation suspension product, a generic version of AstraZeneca's PULMICORT RESPULES treatment.
  AstraZeneca November 20, 2008  
• AstraZeneca to realign supply chain to improve productivity and move closer to customers  AstraZeneca has announced proposed changes to its global manufacturing and supply chain operations as part of its ongoing programme to improve efficiency across the business.
  AstraZeneca November 20, 2008  
• Amgen, Takeda and Millennium provide update on Phase 3 trial of motesanib  Amgen and Millennium announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended.
  Amgen November 19, 2008  
• AstraZeneca enters agreement for authorized generic Pulmicort Respules  AstraZeneca announced that it has entered into a supply and distribution agreement with Par Pharmaceutical to distribute an authorized generic version of budesonide inhalation suspension in the United States in response to the launch 'at risk' of a generic version of this product by Teva.
  AstraZeneca November 19, 2008  
• FDA opens 1st office in China  U.S. officials are launching a new strategy to improve the safety of the vast range of foods and other products imported from China and other countries to the United States. The Food and Drug Administration is opening its first office outside the United States in Beijing.
  Austin American-Statesman (Texas) November 19, 2008  Craig Simons
• FDA responds to AstraZeneca’s citizen petition  On 18 November 2008, the US FDA responded to AstraZeneca's Citizen Petition surrounding the company's concern about the approval of any generic version of PULMICORT RESPULES(R) (budesonide inhalation suspension).
  AstraZeneca November 19, 2008  
• Phase III studies show that vandetanib brings benefits to patients with lung cancer  AstraZeneca announced results from three Phase III studies of ZACTIMA (vandetanib) in combination with chemotherapy agents docetaxel (ZODIAC) and pemetrexed (ZEAL) and as monotherapy (ZEST) in non-small cell lung cancer (NSCLC).
  AstraZeneca November 19, 2008  
• Introgen announces the transfer of its listing of common stock  Introgen Therapeutics announced that it has received notice from the Nasdaq Hearings Panel that the listing of the company's common stock will be transferred from The Nasdaq Global Market to The Nasdaq Capital Market effective with the opening of trading on November 19, 2008.
  Introgen Therapeutics, Inc. November 18, 2008  
• Gov. Perry announces Emerging Technology Fund Investments In DNATriX and Smart Imaging  Gov. Rick Perry announced the state will invest $500,000 and $230,000 respectively through the Texas Emerging Technology Fund (TETF) in DNATriX Inc. and Smart Imaging Technologies Co. of Houston for the commercialization of their innovative technologies.
  Governor of Texas November 18, 2008  

   (next 10 articles)